Syncom Formulations (India) Valuation

Is 524470 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524470 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 524470's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 524470's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524470?

Key metric: As 524470 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524470. This is calculated by dividing 524470's market cap by their current earnings.
What is 524470's PE Ratio?
PE Ratio	55.9x
Earnings	₹331.45m
Market Cap	₹18.54b

524470 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.4x
Enterprise Value/EBITDA	46.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 524470's PE Ratio compare to its peers?

The above table shows the PE ratio for 524470 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.7x
SMSPHARMA SMS Pharmaceuticals	34.1x	n/a	₹20.3b
507747 TTK Healthcare	25.5x	n/a	₹20.4b
590006 Amrutanjan Health Care	43x	n/a	₹20.4b
524164 IOL Chemicals and Pharmaceuticals	20.1x	29.2%	₹20.0b
524470 Syncom Formulations (India)	55.9x	n/a	₹18.5b

Price-To-Earnings vs Peers: 524470 is expensive based on its Price-To-Earnings Ratio (55.9x) compared to the peer average (30.7x).

Price to Earnings Ratio vs Industry

How does 524470's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$71.82m
524652 Ind-Swift	2x	n/a	US$13.29m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 524470 is expensive based on its Price-To-Earnings Ratio (55.9x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is 524470's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524470 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	55.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524470's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

11.6%

27.4%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

-0.4%

58.1%

Venus Remedies

₹4.0b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

-1.3%

-16.9%